Skip to main content

Table 1 The clinicopathological characteristics of samples used for establishing CC PDXs

From: Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies

Variable

All patients

Engrafters

Non-engrafters

Take rate (%)

p

(n = 69)

(n = 44)

(n = 25)

Median age at surgery, years (IQR)

52 (47–58)

51 (45–56)

55 (50, 60)

 

0.907

Histology, n (%)

    

0.865

 SC

56 (81.1)

35 (79.6)

21 (84.0)

62.5

 

 AC

9 (13.1)

6 (13.6)

3 (12.0)

66.7

 Others

4 (5.8)

3 (6.8)

1 (4.0)

75

Tumor stagea, n (%)

   

0.275

 Early

21 (30.4)

12 (27.3)

9 (36.0)

57.1

 

 LACC

28 (40.6)

17 (38.6)

11 (44.0)

60.7

 Advanced

20 (29.0)

15 (34.1)

5 (20.0)

75

Tumor differentiation, n (%)

   

0.915

 Poor

34 (49.3)

22 (50.0)

12 (48.0)

64.7

 

 Moderate

33 (47.8)

21 (47.7)

12 (48.0)

63.6

 Well

2 (2.9)

1 (2.3)

1 (4.0)

50

Tumor size, n (%)

   

0.021

 ≥ 4 cm

46 (66.7)

25 (56.8)

21 (84.0)

54.4

 

 < 4 cm

23 (33.3)

19 (43.2)

4 (16.0)

82.6

Tumor invasion, n (%)

   

0.831

 Superficial

21 (30.4)

13 (29.5)

8 (32.0)

61.9

 

 Deep

48 (69.6)

31 (70.5)

17 (68.0)

64.6

LN metastases, n (%)

   

0.215

 Yes

20 (29.0)

15 (34.1)

5 (20.0)

75

 

 No

49 (71.0)

29 (65.9)

20 (80.0)

59.2

LVSI, n (%)

    

0.109

 Yes

28 (40.6)

21 (47.1)

7 (28.0)

75

 

 No

41 (59.6)

23 (52.9)

18 (72.0)

56.1

SMI, n (%)

    

0.583

 Yes

9 (13.1)

5 (11.4)

4 (16.0)

55.6

 

 No

60 (86.9)

39 (88.6)

21 (84.0)

65

NI, n (%)

    

0.097

 Yes

5 (7.3)

5 (11.4)

0 (0.0)

100

 

 No

64 (92.7)

39 (88.6)

25 (100.0)

60.9

PI, n (%)

    

0.63

 Yes

4 (5.8)

3 (6.9)

1 (4.0)

75

 

 No

65 (94.2)

41 (93.1)

24 (96.0)

63.1

Prognosis, n (%)

    

0.236

 Non-recurrence

57 (82.6)

34 (77.3)

23 (92.0)

59.7

 

 Recurrence

1 (1.4)

1 (2.3)

0 (0.0)

100

 Death

2 (2.9)

2 (4.5)

0 (0.0)

100

 Unknown

9 (13.1)

7 (15.9)

2 (8.0)

77.8

NACT, n (%)

    

0.63

 Yes

4 (5.8)

3 (6.9)

1 (4.0)

75

 

 No

65 (94.2)

41 (93.1)

24 (96.0)

63.1

  1. AC adenocarcinoma, LN lymph node, LVSI lymphatic vascular space invasion, NI nerve invasion, NACT neoadjuvant chemotherapy, PI parametrial invasion, SC squamous carcinoma, SMI surgical margin involvement
  2. a Diagnosis was made according to the 2018 staging system of the International Federation of Gynecology and Obstetrics